These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Age of Bioterrorism: Are You Prepared? Review of Bioweapons and Their Clinical Presentation for Otolaryngologists. Zapanta PE; Ghorab S Otolaryngol Head Neck Surg; 2014 Aug; 151(2):208-14. PubMed ID: 24757076 [TBL] [Abstract][Full Text] [Related]
23. Threats in bioterrorism. I: CDC category A agents. Darling RG; Catlett CL; Huebner KD; Jarrett DG Emerg Med Clin North Am; 2002 May; 20(2):273-309. PubMed ID: 12120480 [TBL] [Abstract][Full Text] [Related]
24. [Bioterrorism]. Sata T Nihon Hoigaku Zasshi; 2005 Oct; 59(2):119-25. PubMed ID: 16296383 [TBL] [Abstract][Full Text] [Related]
25. Diagnosis and management of suspected cases of bioterrorism: a pediatric perspective. Patt HA; Feigin RD Pediatrics; 2002 Apr; 109(4):685-92. PubMed ID: 11927716 [TBL] [Abstract][Full Text] [Related]
26. Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses. Zhu Z; Dimitrov AS; Chakraborti S; Dimitrova D; Xiao X; Broder CC; Dimitrov DS Expert Rev Anti Infect Ther; 2006 Feb; 4(1):57-66. PubMed ID: 16441209 [TBL] [Abstract][Full Text] [Related]
27. Biological agents: weapons of warfare and bioterrorism. Broussard LA Mol Diagn; 2001 Dec; 6(4):323-33. PubMed ID: 11774197 [TBL] [Abstract][Full Text] [Related]
28. Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections. Bregenholt S; Jensen A; Lantto J; Hyldig S; Haurum JS Curr Pharm Des; 2006; 12(16):2007-15. PubMed ID: 16787244 [TBL] [Abstract][Full Text] [Related]
29. Bioterrorism: class A agents and their potential presentations in immunocompromised patients. Richard JL; Grimes DE Clin J Oncol Nurs; 2008 Apr; 12(2):295-302. PubMed ID: 18390465 [TBL] [Abstract][Full Text] [Related]
30. [Recombinant antibodies against bioweapons]. Thullier P; Pelat T; Vidal D Med Sci (Paris); 2009 Dec; 25(12):1145-8. PubMed ID: 20035695 [TBL] [Abstract][Full Text] [Related]
31. Bioterrorism: a new frontier for drug discovery and development. Shailubhai K IDrugs; 2003 Aug; 6(8):773-80. PubMed ID: 12917773 [TBL] [Abstract][Full Text] [Related]
33. [Contemporary control of biological warfare]. Płusa T; Jahnz-Rózyk K Pol Merkur Lekarski; 2002 Mar; 12(69):173-7. PubMed ID: 12053581 [TBL] [Abstract][Full Text] [Related]
34. Zoonoses likely to be used in bioterrorism. Ryan CP Public Health Rep; 2008; 123(3):276-81. PubMed ID: 19006970 [TBL] [Abstract][Full Text] [Related]
35. Therapeutic options for diseases due to potential viral agents of bioterrorism. Bronze MS; Greenfield RA Curr Opin Investig Drugs; 2003 Feb; 4(2):172-8. PubMed ID: 12669378 [TBL] [Abstract][Full Text] [Related]
36. Vaccines against biologic agents: uses and developments. Ales NC; Katial RK Respir Care Clin N Am; 2004 Mar; 10(1):123-46. PubMed ID: 15062232 [TBL] [Abstract][Full Text] [Related]
37. Rapid focused sequencing: a multiplexed assay for simultaneous detection and strain typing of Bacillus anthracis, Francisella tularensis, and Yersinia pestis. Turingan RS; Thomann HU; Zolotova A; Tan E; Selden RF PLoS One; 2013; 8(2):e56093. PubMed ID: 23418519 [TBL] [Abstract][Full Text] [Related]
38. A Bivalent Anthrax-Plague Vaccine That Can Protect against Two Tier-1 Bioterror Pathogens, Tao P; Mahalingam M; Zhu J; Moayeri M; Kirtley ML; Fitts EC; Andersson JA; Lawrence WS; Leppla SH; Chopra AK; Rao VB Front Immunol; 2017; 8():687. PubMed ID: 28694806 [TBL] [Abstract][Full Text] [Related]
39. The medical threat of biological weapons. Atlas RM Crit Rev Microbiol; 1998; 24(3):157-68. PubMed ID: 9800098 [TBL] [Abstract][Full Text] [Related]